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Furlan, Raffaello, Sandro Ardizzone, Laura Palazzolo, Alexandra
Rimoldi, Francesca Perego, Franca Barbic, Maurizio Bevilacqua,
Luca Vago, Gabriele Bianchi Porro, and Alberto Malliani. Sympa-
thetic overactivity in active ulcerative colitis: effects of clonidine. Am J
Physiol Regul Integr Comp Physiol 290: R224–R232, 2006. First pub-
lished August 25, 2005; doi:10.1152/ajpregu.00442.2005.—Previous re-
ports suggest that inflammatory bowel diseases may be accompanied
by abnormalities in the neural autonomic profile. We tested the
hypotheses that 1) an exaggerated sympathetic activity characterizes
active ulcerative colitis (UC) and 2) a reduction of sympathetic
activity by clonidine would be associated with clinical changes of UC.
In 23 patients with UC and 20 controls, muscle sympathetic nerve
activity (MSNA), ECG, blood pressure, and respiration were contin-
uously recorded, and plasma catecholamine was evaluated both at rest
and during a 75° head-up tilt. Autonomic profile was assessed by
MSNA, norepinephrine, epinephrine, spectral markers of low-fre-
quency (LF) cardiac sympathetic (LFRR; normalized units) and high-
frequency (HF) parasympathetic (HFRR; normalized units) modula-
tion and sympathetic vasomotor control (LF systolic arterial pressure;
LFSAP), obtained by spectrum analysis of the R-R interval and systolic
pressure variability. Among UC patients, 16 agreed to be randomly
assigned to 8-wk transdermal clonidine (15 mg/wk, 9 subjects), or
placebo (7 patients). An autonomic profile, Disease Activity Index
(DAI), and endoscopic pattern were compared before and after
clonidine/placebo. At rest, MSNA, heart rate (HR), LFRR, LF/HF, and
LFSAP were higher and HFRR was lower in patients than in controls.
Tilt decreased HFRR and increased MSNA and LFRR less in patients
than in controls. Clonidine decreased HR, MSNA, epinephrine, LFRR,
and increased HFRR, whereas placebo had no effects. Changes of the
autonomic profile after clonidine were associated with reduction of
DAI score. An overall increase of sympathetic activity characterized
active UC. Normalization of the autonomic profile by clonidine was
accompanied by an improvement of the disease.
sympathetic nervous system; microneurography; power spectrum
analysis; tilt test.
IMPORTANCE OF THE AUTONOMIC nervous system in modulating
motility, secretion, and mucosal immunity of the gastrointes-
tinal tract is widely recognized (4, 6, 12, 39, 43). There is
increasing evidence that autonomic abnormalities may play a
role also in the pathophysiology of the gastrointestinal appa-
ratus, namely in inflammatory disorders.
In animals, alterations of the sympathetic nervous system
activity were found to facilitate and sustain local inflammatory
mechanisms in ulcerative colitis (UC) after the onset of mu-
cosal lesions (8). Accordingly, in rats with experimental colitis,
there was a reduced degree of colonic tissue damage if they had
undergone a previous sympathectomy compared with animals
with intact autonomic nervous system (26).
In humans, the attempt to identify whether autonomic alter-
ations are likely to be present in UC has furnished inconclusive
results. The promoting role of an increased overall sympathetic
activity in sustaining the inflammatory process of UC may be
inferred from the fact that psychological stress can reactivate
quiescent UC (42). On the other hand, the increase of para-
sympathetic drive to the organs by nicotine patch was found to
ameliorate the inflammatory state in UC patients (32). How-
ever, these human studies did not address the relationship
between autonomic abnormalities and the activity of the dis-
ease. These aspects may be of paramount importance because
the possibility of manipulating an abnormal autonomic profile
by drugs might result in an amelioration of the disease.
In the present study, we compared the cardiovascular auto-
nomic control of patients with mild, active UC and healthy
controls both at rest and during a tilt maneuver, a stimulus that
promotes an overall increase of the sympathetic activity. The
autonomic profile was assessed by means of the direct record-
ing of postganglionic muscle sympathetic nerve activity
(MSNA) and the evaluation of plasma norepinephrine and
epinephrine levels. Spectral markers of cardiac sympathetic
and vagal modulation of the sinoatrial node activity and of
vascular sympathetic regulation, obtained by power spectrum
analysis of heart period and systolic arterial pressure (SAF)
variability, completed the autonomic assessment of each pa-
tient. As a second aim, we tested the hypothesis that, in a state
of sympathetic overactivity, the neural changes induced by
clonidine administration would be associated with an improve-
ment of the disease.
MATERIALS AND METHODS
Study Design and Population
The present investigation includes two separate parts, as outlined in
Fig. 1. Twenty-three patients with active UC (age, 42 3 yr; 15 men,
8 women) were compared with 20 healthy controls (age, 38  3 yr;
12 men, 8 women), both at rest and during a 75° head-up tilt.
Among the group of patients with active UC, a subgroup of 16
patients (age, 44  4 yr; 12 men, 4 women) agreed to undergo a
second part of the protocol and was randomly assigned to 8-wk of
transdermal clonidine (Catapresan TTS 2; Boehringer-Ingelheim; 15
mg/wk; n 9, 6 men, 3 women; age, 44 6 yr) or placebo patch (n
7; 6 men, 1 female; age, 47  6 yr). All of the subjects attending the
second part of the protocol were studied only in the recumbent
position. Their previous therapy, if any, was maintained unchanged
for the 8 wk of the study (Table 1) and clonidine or placebo patches
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were added. Patches were placed on arms or trunk and changed every
7 days. Two patients had not received any drug before the study
because the diagnosis of UC was made just before their enrollment
(Table 1).
Control subjects were healthy volunteers without evidence of
organic disease on the basis of the interview and physical examina-
tion. Subjects with UC were part of a population attending the
outpatient clinic for inflammatory bowel disease of the gastroenterol-
ogy unit of the hospital, who agreed to participate in the study. UC
was diagnosed on the basis of clinical and radiographic signs, endos-
copy, and pathology criteria. Demographic and clinical features of the
group of patients with UC are reported in Table 1.
Inclusion Criteria
Subjects older than 18 yr with diagnosed UC were eligible to be
enrolled, if they were suffering from clinically and endoscopically
active disease. UC was defined “active” on the basis of a Disease
Activity Index (DAI) score 4 (see below).
Exclusion Criteria
Patients with UC were excluded if hepatic, renal, lung, heart
diseases, infective colitis, secondary causes of autonomic dysfunction,
and pregnancy were present, on the basis of the history, complete
medical evaluation, and routine tests. No subject was enrolled if
contraindications to the use of clonidine were present.
Disease Activity Assessment
Activity of UC was quantified by a DAI (3) that measured stool
frequency, rectal bleeding, endoscopic findings, and the physician’s
evaluation of the disease severity by a 0–3 gravity scale (35). The
highest score, i.e., 12, indicates more than five evacuations than
subject’s normal, blood alone passed, spontaneous bleeding with
ulcerations at the endoscopic evaluation, and severe disease as glo-
bally assessed by the physician. Conversely, a score of 0 indicates
normal stool frequency, no rectal bleeding, normal mucosal appear-
ance during endoscopy, and no clinical signs of disease activity.
Details about parameters, classification, and point scales of DAI are
provided in Table 2.
Truelove and Richards’ 0–4 scale (40) was used to assess the
degree of colonic inflammatory lesions on biopsies obtained during
each of the colonoscopies performed at the time of the first study and
after 8 wk of clonidine/placebo treatment.
Recorded Variables
In every subject, ECG, arterial pressure (Finapres device; Ohmeda,
Louisville, CO), respiratory activity (thoracic bellows), and MSNA
were continuously recorded.
MSNA was obtained by a microneurography technique (41).
Briefly, a unipolar tungsten electrode was placed in the right peroneal
nerve near the fibular head for multiunit postganglionic sympathetic
nerve recording. A reference electrode was inserted subcutaneously
and close to the recording needle. The row neural signal was amplified
Fig. 1. Flow diagram of the study protocol. UC, ulcerative colitis.
Table 1. Demographic and clinical features
of patients with UC
UC Patients
Total number 23
Gender
Male 15 (65)
Female 8 (35)
Age, yr
Mean  SD 42  3
Weight, kg
Mean  SD 68  10
Height, cm
Mean  SD 171  56
Smoking status
Smoker 9 (39)
Former smoker or nonsmoker 14 (61)
Duration of disease, yr
Mean  SD 5.6  1.3
Extent of disease
Proctosigmoiditis 11 (48)
Left-sided colitis 9 (39)
Pancolitis 3 (13)
Therapy
No drug 2 (9)
Systemic steroids (prednisone 25–50 mg/day) 4 (17)
Topical steroids (beclomethasone 3 mg/day) 7 (30)
Mesalamine or sulfasalazine (1.2–2.0 g/day) 21 (91)
Topical mesalamine (2–4 g/day) 16 (70)
Cyclosporin (4 mgkg1day1) 1 (4)
Values are number of patients; values in parentheses are percentages. UC,
ulcerative colitis.
Table 2. Parameters, classification and point scales of the
Disease Activity Index modified from Ref. 3
Parameter Classification
Point
Scales
Clinical, stool frequency (on
a weekly basis)
Normal 0
1–2 evacuations/day  normal 1
3–4 evacuations/day  normal 2
4 evacuations/day  normal 3
Clinical, rectal bleeding None 0
Streaks of blood 1
Evident blood 2
Mostly blood 3
Endoscopy, mucosal
appearance
Normal 0
Mild friability 1
Moderate friability 2
Exudation, spontaneous bleeding 3
Clinical, physician’s rating of
disease activity
Normal 0
Mild 1
Moderate 2
Severe 3
Maximum score 12
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(1,000-fold amplification), fed to a band-pass filter (bandwidth be-
tween 700 and 2,000 Hz), rectified, and integrated (time constant 
0.1 s) by a nerve traffic analyzer system (Bioengineering Dept.,
University of Iowa, Iowa City, IA). Systemic arterial pressure, ECG,
integrated MSNA, and the respiratory signal were digitized at 300
samples/s and stored on the hard disk of a personal computer for
offline analysis. Plasma epinephrine and norepinephrine were mea-
sured on venous blood samples by high-performance liquid chroma-
tography with electrochemical detection.
Every patient underwent a colonoscopy when enrolled in the study.
A second colonoscopy was performed at the end of the 8-wk placebo/
clonidine study only in those patients who agreed to participate in the
second part of the protocol.
Protocol
The experimental protocol was approved by the Hospital Review
Board in Human Research, and written informed consent was pro-
vided by all subjects.
Part 1. After instrumentation and an adequate period of adaptation
on a tilt table, ECG, beat-by-beat arterial pressure, respiratory activity,
and MSNA were continuously recorded for 15 min in the recumbent
position, and a blood sample was obtained for evaluation of plasma
catecholamine. Thereafter, all subjects were tilted at 15° intervals
every 4 min until the 75° head-up position was reached. This position
was maintained for 15 min. At minute 5 of the 75° tilt, a second blood
sample was withdrawn.
Part 2. After having completed part 1 of the protocol, patients with
UC were asked to participate also in part 2 of the study that was
illustrated in detail. The 16 subjects who agreed to take part were
randomly assigned to an 8-wk placebo or a clonidine transdermal
patch. After each period, these patients underwent a second 15-min
data recording, including the direct evaluation of the MSNA and
plasma catecholamine assessment in the recumbent position. In addi-
tion, they were clinically and endoscopically reevaluated by both the
DAI scale and a colonoscopy at the end of the 8-wk period of placebo
or clonidine assumption. We were unable, for ethical reasons, to
perform a crossover between the placebo and clonidine groups be-
cause of the need of a third peroneal nerve puncture for MSNA
recording and colonoscopy in each patient.
Data Analysis
Microneurography recordings were considered to reflect MSNA,
according to criteria previously defined (41). The principles of the
software for data acquisition and autoregressive spectral and cross-
spectral analysis have been described elsewhere (5, 29). Briefly, two
major oscillatory components can be extracted from R-R interval
spontaneous variability (38). A high-frequency (HFRR, 0.25 Hz)
component, the power of which is considered a marker of the vagal
modulation of the sinoatrial node discharge (1), and a low-frequency
(LFRR, 0.10 Hz) component considered, when normalized, an index of
the cardiac sympathetic modulation and of its changes (14, 20, 25,
29). The power of these two different oscillatory components is
computed both in absolute (ms2) and normalized units. Normalized
units are obtained by dividing the absolute power of each spectral
component by total power minus the very low-frequency (LF) com-
ponent (0.03 Hz) and multiplying by 100 (25, 29). The LF-to-HF
ratio quantifies the reciprocal changes of the sympathetic and vagal
modulation of the sinoatrial node discharge (25, 29). LFSAP (0.10 Hz)
can be considered a marker of the sympathetic modulation of vaso-
motor activity (14, 25, 29, 30).
Statistics
Data are expressed as means  SE. One-way ANOVA was used to
assess the differences between patients and controls at rest and to
compare the changes induced by the tilt maneuver between the two
groups.
Modifications induced by clonidine or placebo in respect to the
active phase of the disease were evaluated by Student’s t-test for
paired observations. Differences were considered significant at values
of P  0.05.
RESULTS
Autonomic Profile of UC at Rest
Heart rate was significantly higher in subjects with UC than
in controls, whereas blood pressure and respiratory activity
were similar in the two groups (Table 3). Neural sympathetic
discharge (MSNA) was higher in patients suffering from UC
than in controls (Fig. 2 and Table 3). Plasma norepinephrine
and epinephrine levels were only slightly greater in patients
(Table 3). Figure 3 illustrates examples of power spectrum
analysis of R-R interval and SAP variability and of respiration
in a control subject and in a patient with active UC. Notice that
in the patient, the low-frequency components of both R-R
interval and SAP variability were higher than in the control
subject. Accordingly, LFRR normalized units and LFSAP were
significantly higher in the group of patients than in controls,
whereas the marker of vagal modulation of the sinoatrial node
activity, HFRR, showed an opposite pattern (Table 3). Finally,
the LF-to-HF ratio was greater in UC patients, suggesting a
shift of the cardiac sympathovagal balance toward a sympa-
thetic predominance, compared with controls (Table 3).
Changes Induced by 75° Head-Up Tilt
The gravitational stimulus induced similar changes in heart
rate, blood pressure, respiration, plasma norepinephrine, and
epinephrine in patients with UC and in healthy controls (Table
4). The increase of MSNA in response to tilt was larger in
controls than in UC patients. Figure 4 shows the power spectra
of R-R interval and SAP variability and of respiration during
tilt in the same control subject and patient of Fig. 3. Notice that
the spectral profiles were similar in both individuals. Thus
Table 3. Hemodynamic and respiratory parameters and
indices of autonomic activity in controls and patients with
active UC in recumbent position
Controls UC
SAP, mmHg 1223 1202
DAP, mmHg 742 762
HR, beats/min 632 7530
Resp, cycles/min 171 181
MSNA, bursts/min 162.1 333.5
bursts/100 beats 284 566.3
NE, pg/ml 26631 31639
E, pg/ml 356.0 446.2
RR variance, ms2 2,607597 1,405290
LFRR, ms2 734183 701185
nu 524 742
HFRR, ms2 788209 18847
nu 434 201.8
LF/HF 1.50.2 5.10.9
LFSAP, mmHg2 2.20.5 4.10.6*
SAP, systolic arterial pressure; DAP, diastolic arterial pressure; HR, heart
rate; Resp, respiratory activity; MSNA, muscle sympathetic nerve activity; NE,
norepinephrine; E, epinephrine; RR, R-R interval; LFRR, low frequency com-
ponent of RR variability; HFRR, high frequency component; nu, normalized
units; LFSAP, low frequency component of SAP. *P  0.05 active UC vs.
controls; **P  0.01 active UC vs. controls.
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during tilt, the enhancement of LFRR normalized units and
LF/HF were higher in controls than in UC, and the reduction of
HFRR was more pronounced in controls than in UC subjects
(Table 4).
Autonomic and Clinical Changes After Clonidine
Placebo did not elicit any change in the hemodynamics, in
the indices of autonomic neural control, or in the clinical state
of patients with active disease (Table 5 and Fig. 5). Con-
versely, clonidine administration decreased MSNA (Fig. 5,
bottom), plasma epinephrine levels, and the spectral indices of
cardiac (LFRR normalized units) and vascular (LFSAP) sympa-
thetic activity (Table 6). Accordingly, the LF-to-HF ratio
decreased, and the marker of cardiac vagal modulation HFRR
increased (Table 6).
From the clinical standpoint, the reduction of global neural
sympathetic activity and increase of vagal cardiac modulation
was associated with an improvement of the disease, as globally
assessed by the DAI scale (Fig. 6). This was achieved by a
concomitant amelioration of symptoms (clinical) and of the
endoscopic pattern. Conversely, the colonic histological abnor-
malities (pathology), observed when the disease was active, did
not change significantly after 8 wk of clonidine (Fig. 6,
bottom).
DISCUSSION
Main findings of the present study suggest that, in the
recumbent position, patients with active UC were characterized
by an overall enhancement of sympathetic activity compared
with healthy controls. In addition, patients exhibited a reduced
capability to decrease the marker of cardiac vagal drive and to
increase the indices of cardiac and vascular sympathetic mod-
ulation in response to the gravitational stimulus. Eight-week
Fig. 2. Examples of the recorded variables in a control healthy subject and in
a patient with active UC. Notice that heart rate was slightly higher in the
patient with UC who showed a more pronounced muscle sympathetic nerve
discharge activity (MSNA) than the control. HR, heart rate; AP, arterial
pressure; and Resp, respiratory activity.
Fig. 3. Examples of power spectrum analyses of R-R interval (RR) and
systolic arterial pressure (SAP) variability and Resp in a control subject (C)
and patient with active UC (UC) at rest. Notice that in the control subject, the
power of the low (LFRR)- and high-frequency (HFRR) oscillations of R-R
interval variability were similar, suggesting a balance between the sympathetic
and vagal cardiac modulations. In contrast, in the patient with UC, LFRR was
markedly predominant, indicating a reduced vagal and enhanced sympathetic
activity to the sinoatrial node.
Table 4. Changes induced by the 75° head-up tilt in the
hemodynamic and respiratory parameters, and indices of
autonomic activity in controls and UC subjects
Controls UC
SAP, mmHg 12 24
DAP, mmHg 42 72
HR, beats/min 222 172
Resp, cycles/min 11 11
MSNA, bursts/min 162.2 7.62.3
bursts/100 beats 104 7.55.2
NE, pg/ml 19238 21636
E, pg/ml 3814 3210
RR variance, ms2 606372 568284
LFRR ms2 408353 278202
nu 295 10.53*
HFRR ms2 662189 14244*
nu 305 112
LF/HF 7.91.7 8.92.7
LFSAP, mmHg2 9.12.1 9.84.13
*P  0.05 active UC vs. controls; **P  0.01 active UC vs. controls.
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clonidine administration reduced the sympathetic overactivity
observed at rest in patients with active UC. Changes of the
autonomic profile induced by clonidine were associated with a
clinical and endoscopic improvement.
Autonomic Profile and UC
Results of the present study suggest that the neural sympa-
thetic discharge activity (MSNA) was markedly higher in
subjects with active UC than in healthy controls. In addition,
heart rate, LFRR normalized units, and LF-to-HF ratio were
greater and HFRR was lower in patients, suggesting a shift of
the sympathovagal modulation of the sinoatrial node toward a
sympathetic predominance and parasympathetic reduction,
compared with controls. As to this latter aspect, it must be
pointed out that power spectrum analysis of R-R interval
variability does not provide a direct measure of the neural
autonomic activity directed to the heart, but, rather, it furnishes
a broad noninvasive marker of the relationship between neural
modulation and target organ, i.e., the sinoatrial node respon-
siveness (25, 29, 38).
In patients, despite the elevated values of MSNA, plasma
norepinephrine was only slightly higher than in controls. It
should be recalled that plasma norepinephrine levels provide
imprecise estimate of the global neural sympathetic activity.
Indeed, only 10–20% of the norepinephrine released at the
level of the sympathetic synapses spills into the circulation or
extraneuronal tissues, whereas the large majority undergoes a
reuptake process into the sympathetic neuron by the norepi-
nephrine transporter protein (9, 15). In addition, plasma nor-
epinephrine levels are also dependent on norepinephrine sys-
temic clearance (9). This latter might have been affected in our
study by the likely changes of splanchnic blood flow related to
the colonic inflammatory state, similarly to the modifications in
blood flow redistribution already described in other diseases
(17) during upright posture. Thus changes in norepinephrine
transporter protein efficiency and/or in catecholamine systemic
clearance, which we could not assess in the present study,
might account for the mild increase of plasma norepinephrine
in a set of increased sympathetic discharge activity observed in
our patients with UC.
Taken together, these findings indicate the existence of an
abnormally enhanced sympathetic activity in subjects suffering
from active UC.
Because diarrhea characterizes the active phase of UC, the
overall increase of sympathetic activity observed in patients of
the present study simply could have been related to a contrac-
tion of plasma volume. Indeed, unloading of cardiopulmonary
and arterial baroreceptor afferents produced by plasma hypo-
volemia results in a diminished central inhibitory modulation
of efferent sympathetic activity, which increases its discharge
activity. This leads to vasoconstriction and tachycardia aimed
at maintaining blood pressure values. Such hemodynamic and
neural changes attending a hypovolemic state are likely to be
magnified during the assumption of the upright position, a
condition that promotes the additional activation of sympa-
thetic afferents eliciting excitatory positive feedback reflexes
from the cardiovascular low-pressure areas (24). In the present
study, we did not assess possible plasma volume modifications.
However, the gravitational stimulus used, i.e., the tilt maneu-
ver, induced similar increases in heart rate of both patients and
controls. In addition, in UC patients, heart rate was stable and
did not show the typical slow increase over time observed in
conditions characterized by declined plasma volume, such as
after weightlessness (27). These findings suggest that the
sympathetic overactivity observed in UC at rest is unlikely to
be a simple compensatory response to a contraction of plasma
volume because it has been also observed in a subset of
patients with orthostatic intolerance (17). In addition, if a
Table 5. Hemodynamics respiratory activity, indices of
autonomic activity, and hematologic parameters in 7 UC
subjects with active disease (symptomatic) and after placebo
Symptomatic After Placebo
SAP, mmHg 1253 1265
DAP, mmHg 814 753
HR, beats/min 683 662
Resp, cycles/min 172.4 151.8
MSNA, bursts/min 404.0 394.5
bursts/100 beats 615.9 636.0
NE, pg/ml 30367 33956
E, pg/ml 38.513.4 36.517
RR variance, ms2 1,278351 1,614350
LFRR ms2 49994 511196
nu 714 654
HFRR, ms2 15856 15656
nu 20.64 19.84
LF/HF 5.462.3 3.90.6
LFSAP, mmHg2 4.90.6 5.20.8
Hb, g/dl 12.90.9 13.30.9
RBC,  103/mm3 5,115295 4,996194
Hct, % 39.61.6 40.52.3
Total protein, g/dl 7.30.34 7.120.13
RBC, red blood cells; Hb, hemoglobin; Hct, hematocrit cell pack.
Fig. 4. Same subjects in Fig. 3 are considered during the 75° head-up tilt.
Notice that the power spectra of R-R interval and SAP variability were similar
in both individuals. Compared with Fig. 3, the expected increase of LFRR and
LFSAP was reduced in the patient compared with the control subject.
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contracted circulatory volume had been present in patients with
UC, the sympathetic response required to adjust to the gravi-
tational stress would have produced a far greater increase of
sympathetic efferent traffic. In addition, a larger decrease of
cardiac vagal drive would have been evident. Conversely,
increase of MSNA and LFRR normalized units and decrease of
HFRR during tilt were less pronounced in subjects with UC
than in controls, indicating a reduced capability to adapt to
such an excitatory stimulus.
As to the potential mechanisms subserving the sympathetic
overactivity in active UC, it can be hypothesized that mediators
locally released by the inflamed gut, such as substance P (2, 7,
19), cytokines (7), and adenosine (2) might induce a chronic
stimulation of enteric visceral afferents, resulting in an abnor-
mal afferent impulse traffic to the spinal cord and brain stem.
This may induce an increase in the discharge pattern of the
Fig. 5. Neural sympathetic discharge activity of two patients
with active UC (left), after placebo, and clonidine. Notice that
MSNA was unchanged after placebo administration, whereas it
was significantly reduced after clonidine.
Table 6. Hemodynamics, respiratory activity, indices of
autonomic activity, and hematologic parameters in 9 UC
subjects with active disease (symptomatic)
and after clonidine
Symptomatic After Clonidine
SAP, mmHg 1204 1164
DAP, mmHg 733 753
HR, beats/min 794 774
Resp, cycles/min 171.2 161.5
MSNA, bursts/min 324.6 214.9*
bursts/100 beats 58.58.9 4110.3*
NE, pg/ml 32963 17640
E, pg/ml 477.6 307.2*
RR variance, ms2 1,500492 3,0971393
LFRR, ms2 798310 879518
nu 762.8 476*
HFRR, ms2 20071 1,177815
nu 213 383*
LF/HF 5.01.1 1.30.2*
LFSAP mmHg2 4.50.9 3.00.7
Hb, g/dl 14.20.5 14.10.5
RBC,  103/mm3 4,779147 4,737177
Hct, % 42.71.6 41.91.7
Total protein, g/dl 6.970.17 7.010.21
*P  0.05 After Clonidine vs. Symptomatic.
Fig. 6. Modifications in the severity of disease as assessed by the global
Disease Activity Index (DAI) and clinical, endoscopic, and pathology
scales after 8 wk of transdermal placebo and clonidine. Clinical scores and
endoscopy scales are part of DAI (see Table 2). In the vertical axis, 0
indicates no activity of the disease and absence of symptoms or endoscopic
and pathology abnormalities. Notice that clonidine administration was
associated with a significant improvement of disease and amelioration of
the endoscopic pattern. Pathology changes after 8 wk of drug therapy were
less consistent. *P  0.05 vs. symptomatic phase of the disease (indicated
by week 0).
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sympathetic efferent neurons that, in turn, may increase cyto-
kines release (10). Trophic changes (7, 21) and secondary
alterations of blood flow regulation (19) might also sustain the
vicious circle linking local gut inflammation and sympathetic
activation (19).
It must be pointed out that a facilitating role played by the
sympathetic nervous system in sustaining the local inflamma-
tory mechanisms in experimental UC has been previously
suggested by animal studies (8, 26). Indeed, sympathetic ac-
tivity was found to promote local inflammatory mechanisms in
UC after the onset of mucosal lesions (8). A reduced degree of
colonic tissue damage was also observed in conscious rats with
experimental colitis that had previously undergone sympathec-
tomy compared with animals with an intact autonomic nervous
system (26). However, it must be emphasized that other au-
thors (18) described a reduced release of noradrenaline from
myenteric plexus preparations of the inflamed distal colon and
in noninflamed gut sites, suggesting a possible disruption,
instead of an enhancement, of enteric sympathetic function in
experimental UC.
The overall increase of sympathetic activity observed in UC
patients of the present investigation is also in keeping with the
data obtained by other studies performed in humans with active
disease. In UC, the catecholamine content of rectal mucosa
resulted in enhanced (31) and increased adrenergic innervation
(21). Moreover, a relationship between autonomic hyperre-
flexia and duration and gravity of the disease has been ob-
served in patients with UC on the basis of conventional
autonomic tests, thus indirectly suggesting the existence of a
hyperadrenergic condition (34).
Finally, it should be emphasized that patients with active UC
in the present study showed reduced values of HFRR, both in
absolute and normalized units, suggesting a concomitant de-
crease of the vagal activity to the heart. This might reflect an
overall diminished efficiency of the cholinergic anti-inflamma-
tory pathway (39) to the gastrointestinal tract, a mechanism
that might help maintain the bowel inflammatory state.
Autonomic and Clinical Changes After Clonidine
In nine subjects with acute UC, 8-wk sympathoplegic ther-
apy resulted in a readjustment of the autonomic profile and in
a concomitant clinical improvement of the disease. This find-
ing further highlights the crucial role played by a sympathetic
overactivity in sustaining the active phase of UC. Indeed, after
clonidine, MSNA and plasma epinephrine decreased signifi-
cantly. The LF-to-HF ratio and LFRR normalized units de-
creased, and the index of cardiac parasympathetic activity
HFRR increased, suggesting a reduced sympathetic and en-
hanced parasympathetic modulation to the sinoatrial node.
As to the observed increase of parasympathetic modulation
to the heart after clonidine, our results are in keeping with
previous findings by Lazzeri et al. (22) in mild hypertensive
patients and by Tank and colleagues obtained both in animals
(37) and healthy humans (36). This latter investigation (36)
indicates that 2-adrenoreceptor stimulation by clonidine in-
creased baroreflex-mediated bradycardia during baroreceptor
loading (36), a finding consistent with an increased cardiac
parasympathetic tone.
Clonidine may shift the cardiac autonomic control toward a
parasympathetic predominance by different mechanisms. In-
deed, in animals, clonidine was found to reduce sympathetic
outflow from the ventrolateral medulla neurons (16), thus
leading to a relative parasympathetic predominance. In addi-
tion, it may stimulate 2-adrenoreceptors of the vagus dorsal
motor nuclei (33), inducing direct central increase of cardiac
parasympathetic modulation. Finally, peripheral stimulation of
cardiac presynaptic 2-adrenoreceptors may mediate ACh
release from cholinergic neurons of the heart (28) mimicking
parasympathetic stimulation.
Plasma norepinephrine levels were only slightly reduced
when UC improved. This finding might reflect the fact that
sensitivity of plasma norepinephrine in sensing changes of the
sympathetic activity may be limited, as previously observed in
hypertensive patients (13).
The global clinical amelioration of the disease observed in
the present study after clonidine is in accordance with the
clinical and endoscopic findings observed by Lechin et al. (23),
who had previously administered clonidine to patients with
UC to mimic the beneficial effects of tioperazine on colonic
motility.
Finally, a puzzling finding of the present work is the more
pronounced reduction after clonidine of clinical symptoms and
endoscopy abnormalities compared with the histological pat-
tern. Indeed, after clonidine, histology was unchanged com-
pared with the active phase of UC. However, permanent
architectural abnormalities have been described to persist for
months even in patients with clinically and endoscopically
quiescent colitis (11). Therefore, the complete histological
recovery might be achieved in the UC patients of the present
work later than our 8-wk follow-up period.
Study Limitations
It must be pointed out that the sympathetic overactivity
observed in UC patients of the present study and the reduced
cardiac vagal modulation may not be a disease-specific feature
of UC but rather a generic autonomic trait due to the inflam-
matory state. With respect to this issue, the design of the
present study does not allow any conclusion because the
autonomic profile of other types of colitis, such as infectious,
uremic, or autoimmune diseases were not assessed. However,
although not disease specific, the sympathetic overactivity
observed in the active phase of UC seems to play a crucial
role in generating and sustaining the bowel inflammatory
state, given the fact that the administration of a sympatho-
plegic drug, such as clonidine, was associated with a clinical
amelioration of the disease, whereas the placebo was inef-
fective.
As to the use of clonidine, the present investigation must not
be considered a pharmacological trial. Instead, we focused on
one of the potential pathophysiological mechanisms underly-
ing the acute phase of UC. Given the finding of an abnormally
increased sympathetic activity, we tried to reduce it by giving
a centrally acting sympathoplegic drug, such as clonidine.
Restoration of an autonomic profile, similar to that observed in
healthy controls, was associated with a clinical and endoscopic
improvement of the disease.
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Perspectives
In the present study, we reported findings supporting an
important role of sympathetic activity in the pathophysiology
of UC. Moreover, the association between a reduction of
sympathetic overactivity by clonidine and the clinical improve-
ment of the disease is striking and raises the possibility that a
2-adrenoreceptor agonist might be routinely added to a reg-
ular therapeutic regimen in UC, thus possibly decreasing the
need of a large dosage of other drugs, such as steroids, and
increasing patient drug compliance. However, specifically de-
signed clinical trials are needed to evaluate whether drug
manipulation of autonomic profile might represent an addi-
tional therapy for UC.
In conclusion, our observations highlight the crucial role
played by an enhanced sympathetic activity, possibly in
maintaining the inflammatory process of the gut. In this
context, clonidine administration was found to reduce the
abnormally increased sympathetic activity and improve
clinically active UC.
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